Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fengnian Zhuang

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Langenbeck'S Archives of Surgery|January 22, 2026
Neoadjuvant chemoradiotherapy versus neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma with three-field lymph node dissectionFengNian Zhuang, JunPeng Lin, FangZhou Lin, et al.
Updates in Surgery|February 28, 2024
The prognostic significance of right paratracheal lymph node dissection numbers in right upper lobe non-small cell lung cancerFengNian Zhuang, JunPeng Lin, WeiJie Chen, et al.
Nature Communications|January 8, 2026
Crystallographic microstructure engineering for artificial solid electrolyte interphases toward stable zinc electrodeHongyu Cao, Fengnian Zhuang, Yanfei Wang, et al.
Journal of Cancer Research and Clinical Oncology|October 25, 2024
Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysisPeiyuan Wang, Yujie Chen, Mengxia Lei, et al.
Nature Communications|November 3, 2025
Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)Peiyuan Wang, Yujie Chen, Feng Wang, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Langenbeck'S Archives of Surgery|January 22, 2026
Neoadjuvant chemoradiotherapy versus neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma with three-field lymph node dissectionFengNian Zhuang, JunPeng Lin, FangZhou Lin, et al.
Updates in Surgery|February 28, 2024
The prognostic significance of right paratracheal lymph node dissection numbers in right upper lobe non-small cell lung cancerFengNian Zhuang, JunPeng Lin, WeiJie Chen, et al.
Nature Communications|January 8, 2026
Crystallographic microstructure engineering for artificial solid electrolyte interphases toward stable zinc electrodeHongyu Cao, Fengnian Zhuang, Yanfei Wang, et al.
Journal of Cancer Research and Clinical Oncology|October 25, 2024
Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysisPeiyuan Wang, Yujie Chen, Mengxia Lei, et al.
Nature Communications|November 3, 2025
Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)Peiyuan Wang, Yujie Chen, Feng Wang, et al.
Pageof 1